Artelo Biosciences, Inc. (ARTL)
$
1.03
+0.03 (2.91%)
Key metrics
Financial statements
Free cash flow per share
-2.8277
Market cap
3.4 Million
Price to sales ratio
0
Debt to equity
0.0032
Current ratio
18.3587
Income quality
0.7942
Average inventory
0
ROE
-0.6280
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies aimed at modulating the endocannabinoid system, recently incurred an income tax expense of -$209,000.00 indicating its tax obligations. In assessing its operational efficiency, the gross profit ratio stands at 0.00 which reflects the effectiveness of the company's production and sales efforts. With operating expenses totaling $10,287,000.00 the company has accounted for the various costs associated with its operations. Artelo also reported an income before tax of -$10,083,000.00 showcasing its pre-tax profitability, while the gross profit reached $0.00 highlighting the company's profitability derived from its core activities. The product candidate pipeline includes promising developments such as ART27.13, a synthetic G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal aimed at addressing inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for the treatment of prostate and breast cancer, as well as PTSD. Collaborating with Trinity College Dublin, Artelo is investigating ART27.13 specifically for cancer cachexia, demonstrating its commitment to addressing unmet medical needs. Founded in 2011 and originally named Reactive Medical, Inc., the company rebranded to Artelo Biosciences, Inc. in April 2017 and is headquartered in Solana Beach, California. In terms of financial accessibility, the stock is affordable at $1.01 making it suitable for budget-conscious investors. However, it has a low average trading volume of 421,468.00 indicating lower market activity. With a market capitalization of $3,379,461.00 Artelo is classified as a small-cap player within the biopharmaceutical sector. It is recognized as a key player in the Biotechnology industry, contributing significantly to the overall landscape of healthcare innovation. Positioned in the Healthcare sector, Artelo Biosciences, Inc. drives innovation and growth, reflecting its strategic focus on developing therapeutic solutions that leverage the endocannabinoid system for various medical applications.
What is Artelo Biosciences, Inc. (ARTL)'s stock forecast?
Analysts predict Artelo Biosciences, Inc. stock to fluctuate between $0.82 (low) and $1.59 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Artelo Biosciences, Inc.'s market capitalization?
As of 2025-05-14, Artelo Biosciences, Inc.'s market cap is $3,379,461, based on 3,281,030 outstanding shares.
How does Artelo Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Artelo Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Artelo Biosciences, Inc. (ARTL) stock?
To buy Artelo Biosciences, Inc. (ARTL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ARTL. Place an order (Market, Limit, etc.).
What is the best time to invest in Artelo Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Artelo Biosciences, Inc. stock ever split?
Artelo Biosciences, Inc.'s last stock split was 1:15 on 2022-08-10.
How did Artelo Biosciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$3.49 | Growth: -41.54%.
Where can I find Artelo Biosciences, Inc.'s investor relations reports?
Visit https://www.artelobio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Artelo Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Artelo Biosciences, Inc. stock?
All-time high: $55.05 (2021-02-12) | All-time low: $0.82 (2025-04-09).
What are the key trends affecting Artelo Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
16 days ago
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter
zacks.com
a month ago
ASTS, ASEKY and ARTL have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2025.
globenewswire.com
a month ago
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK.
zacks.com
2 months ago
APEMY, ARTL and CIGI have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2025.
zacks.com
2 months ago
ARTL, KW and KRP have been added to the Zacks Rank #5 (Strong Sell) List on March 6, 2025.
globenewswire.com
2 months ago
SOLANA BEACH, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today provided a business update and announced its financial and operational results for the fiscal year ended December 31, 2024.
globenewswire.com
3 months ago
SOLANA BEACH, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).
globenewswire.com
3 months ago
SOLANA BEACH, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced that it will be presenting data on ART12.11, a proprietary cocrystal composed of cannabidiol (CBD) and tetramethylpyrazine (TMP), at the International Medical Cannabis Conference (IMCCB-25) held at the University of Bern, Switzerland February 13-14, 2025.
globenewswire.com
4 months ago
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected during the first half 2025 SOLANA BEACH, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, or dermatologic and neurological conditions, today announced the completed safety review of the first cohort of eight healthy volunteers in the Company's Phase 1 study of ART26.12.
globenewswire.com
5 months ago
Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment Phase 1 data from the CAReS trial showed an attractive safety profile and promising activity from daily ART27.13 administration with two-thirds of participants having stabilized or reversed weight loss at one month of treatment
See all news
